Axsome Pharma's Q1 Sales Keep Record-High Momentum
Axsome Pharmaceuticals reported first‑quarter sales that matched analysts' expectations, extending its run of record‑high revenue growth. The article points to strong performance of its neurology drug pipeline and optimism about upcoming FDA filings.
Advertisement: Article Inline